Related Experiment Video
Updated: Feb 13, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Abstract:
High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation.
Insights
This study explored personalized treatments for high-grade gliomas (HGGs) using 3D models. Combination therapies showed promise, identifying biomarkers and resistance mechanisms for improved HGG treatment strategies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- High-grade gliomas (HGGs) present significant challenges due to aggressive nature, poor prognoses, and limited therapeutic options.
- Current treatment strategies for HGGs often lack efficacy, necessitating novel approaches for patient care.
Purpose of the Study:
- To identify individualized treatment strategies and predictive biomarkers for high-grade gliomas (HGGs).
- To investigate drug sensitivity, resistance mechanisms, and effective combination therapies in HGGs using patient-derived models.
Main Methods:
- Combined genomic and transcriptomic profiling of patient-derived HGG tumors.
- Utilized 3D culture models for ex vivo drug sensitivity testing of single agents and combinations.
- Analyzed correlations between drug response, transcriptional features, and genomic alterations.
Main Results:
- Single agents showed limited efficacy, but PI3K, epigenetic, and survival/senescence pathway inhibitors were effective in select cases.
- Drug sensitivity was linked to transcriptional profiles, with heterogeneity identified as a resistance mechanism.
- Bromodomain and extraterminal domain inhibition showed efficacy in mesenchymal subtypes, while PI3K signaling impacted response.
- Combination therapies demonstrated significantly higher efficacy than single agents in most tested strategies (58-77%).
Conclusions:
- Identified specific HGG vulnerabilities and potential biomarkers for targeted therapies.
- Elucidated resistance mechanisms, including tumor heterogeneity and PI3K signaling.
- Demonstrated the potential of combination therapies for improving HGG treatment outcomes, warranting clinical validation.
Related Concept Videos
Mechanical Protein Functions
Genomics
Mechanical Protein Function
Genome Size and the Evolution of New Genes
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

